Pre-Open Stock Movers 08/09: (HIIQ) (MWW) (VSLR) Higher; (DRYS) (TUBE) (FCSC) Lower (more...)

August 9, 2016 9:21 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Pre-Open Stock Movers

Health Insurance Innovations (NASDAQ: HIIQ) 32% HIGHER; reported Q2 EPS of $0.27, $0.21 better than the analyst estimate of $0.06. Revenue for the quarter rose 95.6% to $44.5 million versus the consensus estimate of $37.11 million. GUIDANCE: Health Insurance Innovations sees FY2016 EPS of $0.55-$0.65, versus prior guidance of $0.38-$0.42 and the consensus of $0.43. Health Insurance Innovations sees FY2016 revenue of $155-165 million, versus prior guidance of $138-144 million and the consensus of $144.94 million.

DryShips (NASDAQ: DRYS) 26% LOWER; reported Q2 EPS of ($0.34), versus ($54.17) reported last year. Revenue for the quarter came in at $13.2 million, versus $403.2 million reported last year. In talks with lenders for debt restructuring.

Monster Worldwide, Inc. (NYSE: MWW) 23.1% HIGHER; Randstad Holding nv and Monster Worldwide announced the signing of a definitive agreement under which Randstad will acquire Monster. Under the terms of themerger agreement, Randstad will pay $3.40 per share in cash, or a total purchase price of approximately $429 million (enterprise value).

TubeMogul (NASDAQ: TUBE) 21.6% LOWER; reported Q2 EPS of ($0.11), $0.04 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $55.4 million versus the consensus estimate of $58.14 million. GUIDANCE: TubeMogul sees Q3 2016 revenue of $53-55 million, versus the consensus of $57.5 million. TubeMogul sees FY2016 revenue of $217-221 million, versus the consensus of $229.12 million.

Fibrocell Science, Inc. (Nasdaq: FCSC) 20.4% LOWER; announced that it has terminated the previously announced underwritten public offering of common stock and warrants in order to enter into another financing transaction on more favorable terms. The financing transaction provides for the issuance of up to $25.0 million in aggregate principal amount of convertible promissory notes (the Notes) and warrants to purchase common stock (the Warrants) to investors in a private placement in one or more closings (the Financing). The Financing is greater than 50% subscribed and is not subject to any minimum aggregate investment amount. The initial closing of the Financing is expected to occur as soon as reasonably possible. Fibrocell intends to use the net proceeds of the Financing for the continued clinical and pre-clinical development of its product candidates and for other general corporate purposes.

MaxLinear (NYSE: MXL) 14.8% LOWER; reported Q2 EPS of $0.50, $0.06 better than the analyst estimate of $0.44. Revenue for the quarter came in at $101.7 million versus the consensus estimate of $101.94 million. GUIDANCE: MaxLinear sees Q3 2016 revenue of $94-98 million, versus the consensus of $104.22 million.

Wayfair (NYSE: W) 14.5% LOWER; reported Q2 EPS of ($0.43), $0.02 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $755.7 million versus the consensus estimate of $782.41 million.

Manitowoc (NYSE: MTW) 12.8% LOWER; reported Q2 EPS of $0.04, in-line with the analyst estimate of $0.04. Revenue for the quarter came in at $457.7 million versus the consensus estimate of $463.98 million.

NeoPhotonics (NYSE: NPTN) 12.3% LOWER; reported Q2 EPS of $0.15, $0.01 better than the analyst estimate of $0.14. Revenue for the quarter came in at $99.1 million versus the consensus estimate of $101.82 million. GUIDANCE: NeoPhotonics sees Q3 2016 EPS of $0.09-$0.17, versus the consensus of $0.19. NeoPhotonics sees Q3 2016 revenue of $100-106 million, versus the consensus of $107.6 million.

Rogers (NYSE: ROG) 10.7% LOWER; reported Q2 EPS of $0.88, $0.05 better than the analyst estimate of $0.83. Revenue for the quarter came in at $157.5 million versus the consensus estimate of $162.26 million. GUIDANCE: Rogers sees Q3 2016 EPS of $0.69-$0.79, versus the consensus of $0.92. Rogers sees Q3 2016 revenue of $150-160 million, versus the consensus of $165.3 million.

Vivint Solar (NYSE: VSLR) 9.7% HIGHER; reported Q2 EPS of ($0.49), $0.09 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $34.9 million versus the consensus estimate of $24.98 million. Upgraded at Oppenheimer.

Vericel (NASDAQ: VCEL) 9.2% LOWER; reported Q2 EPS of ($0.21), $0.05 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $12.8 million versus the consensus estimate of $15.05 million. As of June 30, 2016, the company had $9.8 million in cash compared to $14.6 million in cash at December 31, 2015.

Castlight Health (NYSE: CSLT) 8% HIGHER; reported Q2 EPS of ($0.11), $0.02 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $23.6 million versus the consensus estimate of $23.09 million Castlight Health sees FY2016 EPS of ($0.40)-($0.42), versus the consensus of ($0.41). Castlight Health sees FY2016 revenue of $99-102 million, versus the consensus of $100.6 million.

IAMGOLD Corporation (NYSE: IAG) 7.6% LOWER; announced that it has entered into an agreement with a syndicate of underwriters led by TD Securities Inc., National Bank Financial Inc. and Morgan Stanley Canada Ltd., pursuant to which they have agreed to purchase, on a bought deal basis, 38,850,000 common shares of the Company at a price of $5.15 per common share (the "Offering Price"), for aggregate gross proceeds to the Company of approximately $200 million (the "Offering"). The underwriters will also have the option, exercisable in whole or in part, at any time up to 30 days following the closing of the Offering, to purchase up to an additional 5,827,500 common shares at the Offering Price to cover over-allotments, if any. In the event that the option is exercised in its entirety, the aggregate gross proceeds of the Offering to the Company will be approximately $230 million.

Nevro (NYSE: NVRO) 7.5% HIGHER; reported Q2 EPS of ($0.31), $0.16 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $55.4 million versus the consensus estimate of $45.11 million. GUIDANCE: Nevro sees FY2016 revenue of $210-220 million, versus the consensus of $188.7 million. For earnings history and earnings-related data on Nevro (NVRO) click here.

Valeant Pharma (NYSE: VRX) 6.3% HIGHER; reported Q2 EPS of $1.40, $0.08 worse than the analyst estimate of $1.48. Revenue for the quarter came in at $2.42 billion versus the consensus estimate of $2.46 billion. Valeant Pharma reaffirmed FY2016 guidance. Adjusted EBITDA (non-GAAP) is expected to be in the range of $4.80 - $4.95 billion, in-line with consensus, although many expected the company to lower EBITDA guidance.

Endo Int'l (NASDAQ: ENDP) 5% HIGHER; reported Q2 EPS of $0.86, $0.12 better than the analyst estimate of $0.74. Revenue for the quarter came in at $921 million versus the consensus estimate of $864.34 million. Company affirms full year 2016 revenue and adjusted diluted EPS financial guidance.

Gap Inc. (NYSE: GPS) 5% LOWER; comparable sales for July 2016 were down 4 percent versus a 3 percent decrease last year.

Bojangles' (NASDAQ: BOJA) 4.8% LOWER; reported Q2 EPS of $0.27, $0.04 better than the analyst estimate of $0.23. Revenue for the quarter came in at $131.6 million versus the consensus estimate of $132.77 million. GUIDANCE: Bojangles' sees FY2016 EPS of $0.88-$0.92, versus prior guidance of $0.89-$0.93 and the consensus of $0.90. Bojangles' sees FY2016 revenue of $530-533 million, versus prior guidance of $535-543 million and the consensus of $540.67 million.

Phillips 66 Partners LP (NYSE: PSXP) 4.8% LOWER; announced the pricing of its underwritten public offering of 6,000,000 common units representing limited partner interests in the Partnership at $50.22 per common unit.

Sina Corp (NASDAQ: SINA) 4.4% HIGHER; reported Q2 EPS of $0.27, $0.12 better than the analyst estimate of $0.15. Revenue for the quarter came in at $244 million versus the consensus estimate of $231.69 million. GUIDANCE: Sina Corp sees FY2016 revenue of $950-1000 million, versus prior guidance of $850-950 million and the consensus of $951.6 million.

ZELTIQ Aesthetics (NASDAQ: ZLTQ) 4.4% HIGHER; reported Q2 EPS of ($0.12), may not compare to the analyst estimate of ($0.05). Revenue for the quarter came in at $89.5 million versus the consensus estimate of $79.68 million. GUIDANCE: ZELTIQ Aesthetics sees FY2016 revenue of $340-350 million, versus the consensus of $323.33 million.

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) 4.2% LOWER; announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a price to the public of $96.00 per share.

Microchip Technology (NASDAQ: MCHP) 3.6% HIGHER; reported Q1 EPS of $0.84, $0.10 better than the analyst estimate of $0.74. Revenue for the quarter came in at $799.4 million versus the consensus estimate of $821.41 million.

B&G Foods, Inc. (NYSE: BGS) 3.6% LOWER; announced that it has priced its offering of 3,750,000 shares of its common stock at a price to the public of $49.00 per share.

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) 3.5% LOWER; announced that it intends to offer and sell, subject to market and other conditions, $200,000,000 of its common stock in an underwritten public offering.

United States Steel Corporation (NYSE: X) 3% LOWER; commenced an underwritten public offering of 17,000,000 shares of common stock. The Company intends to grant the underwriters a 30-day option to purchase up to 2,550,000 additional shares of common stock from the Company.

MannKind (NASDAQ: MNKD) 2% LOWER; reported Q2 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06). Cash and cash equivalents at June 30, 2016 were $63.7 million, compared to $27.7 million at March 31, 2016.

LendingClub (NYSE: LC) 2% LOWER; earnings and CFO Carrie Dolan resigns.

Rackspace (NYSE: RAX) 2% LOWER; reported Q2 EPS of $0.38, $0.16 better than the analyst estimate of $0.22. Revenue for the quarter came in at $524 million versus the consensus estimate of $521.19 million. Rackspace sees Q3 2016 revenue of $510-515 million, versus the consensus of $530.14 million.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

Morgan Stanley, Earnings, Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers

Add Your Comment